MNPR NASDAQ
Monopar Therapeutics Inc.
1W: -3.2%
1M: -14.2%
3M: -33.1%
YTD: +8.8%
1Y: -11.9%
3Y: +3050.9%
5Y: +188.2%
$71.84
+1.30 (+1.84%)
Weekly Expected Move ±6.9%
$61
$66
$71
$76
$80
Credit Risk of going bust: lower than 91% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Monopar Therapeutics Inc. would be worth roughly what it owes.
Total debt $108K against a stock market value of $482.2M.
Distance to default 14.47 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $54K (short-term plus half of long-term), stock volatility 61.8%; Altman Z'' 36.40. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Monopar Therapeutics Inc. would be worth roughly what it owes.
Total debt $108K against a stock market value of $482.2M.
Distance to default 14.47 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $54K (short-term plus half of long-term), stock volatility 61.8%; Altman Z'' 36.40. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$0M
Revenue
+0.0% YoY
$-18M
Net Income
-3.1% YoY
$-3,256M
Free Cash Flow
-33085.6% YoY
0.0%
Gross Margin
0.0%
Op. Margin
0.0%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
⚠️ Cash Burn Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE-19.5%
ROA-18.9%
ROIC523.8%
Valuation
P/E-30.7
P/B4.7
EV/EBITDA-36.8
Leverage
Debt/Equity0.00
Current Ratio33.56
Interest Cov.0.0x
Quality Scores
Piotroski F2/9
Altman Z114.78
Beneish M0.00